Ectrims 2024 Conference Review

October 14, 2024 | Education, Event, Research, Training

Dr. John Mottershead has reviewed 11 presentations he found particularly interesting.

Those topics are:
–  Revised McDonald criteria 2023
–  Does high-dose simvastatin slow progression of disability in SPMS?
–  Efficacy of tolebrutinib in non-relapsing SPMS: the HERCULES trial
–  New clinical subtypes of MS identified
–  Unveiling specialists’ views on MS prognostication
–  Misdiagnosis of MS in an adult neurogenetics clinic
–  Safety and efficacy of frexalimab in RMS
–  Short-term B cell depletion results in long-term freedom from disease activity in some RMS patients
–  Impact of alternate-day fingolimod tapering on rebound disease activity in MS
–  B cell tailored dosing vs standard interval dosing of ocrelizumab
–  High efficacy treatment discontinuation vs continuation in patients older than 50 with stable MS

Click here to download PDF of the ECTRIMS_2024_Conference_Review

Or click here to view online.

Other resources:

Click here to watch the podcasts.